Chad Heatwole

Summary

Affiliation: University of Rochester
Country: USA

Publications

  1. doi request reprint The diagnosis and treatment of myotonic disorders
    Chad R Heatwole
    Department of Neurology, Box 673, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, New York, New York 14642, USA
    Muscle Nerve 47:632-48. 2013
  2. pmc Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1)
    Chad Heatwole
    University of Rochester, Rochester, NY, USA
    Neurology 79:348-57. 2012
  3. pmc Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study
    Chad Heatwole
    Department of Neurology, University of Rochester, Rochester, NY 14642, USA
    J Clin Neuromuscul Dis 13:85-94. 2011
  4. pmc Laboratory abnormalities in patients with myotonic dystrophy type 2
    Chad Heatwole
    Neuromuscular Division, Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Arch Neurol 68:1180-4. 2011
  5. pmc Open-label trial of recombinant human insulin-like growth factor 1/recombinant human insulin-like growth factor binding protein 3 in myotonic dystrophy type 1
    Chad R Heatwole
    University of Rochester Medical Center, Rochester, NY 14642, USA
    Arch Neurol 68:37-44. 2011
  6. ncbi request reprint International Education Issues: practicing and teaching international neurology: the Krakow experience
    Chad Heatwole
    The University of Rochester, 174 Edgemont Rd, Rochester, NY 14620, USA
    Neurology 69:1721-3. 2007
  7. ncbi request reprint Laboratory abnormalities in ambulatory patients with myotonic dystrophy type 1
    Chad R Heatwole
    Neuromuscular Disease Center, Strong Memorial Hospital, University of Rochester, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Arch Neurol 63:1149-53. 2006
  8. ncbi request reprint Extreme spindles: a distinctive EEG pattern in Mycoplasma pneumoniae encephalitis
    Chad R Heatwole
    University of Rochester, NY, USA
    Neurology 64:1096-7. 2005
  9. ncbi request reprint The nondystrophic myotonias
    Chad R Heatwole
    Department of Neurology, University of Rochester, Rochester, New York, USA
    Neurotherapeutics 4:238-51. 2007
  10. pmc Reevaluating measures of disease progression in facioscapulohumeral muscular dystrophy
    Jeffrey M Statland
    Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
    Neuromuscul Disord 23:306-12. 2013

Collaborators

Detail Information

Publications11

  1. doi request reprint The diagnosis and treatment of myotonic disorders
    Chad R Heatwole
    Department of Neurology, Box 673, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, New York, New York 14642, USA
    Muscle Nerve 47:632-48. 2013
    ..Muscle Nerve 47: 632-648, 2013...
  2. pmc Patient-reported impact of symptoms in myotonic dystrophy type 1 (PRISM-1)
    Chad Heatwole
    University of Rochester, Rochester, NY, USA
    Neurology 79:348-57. 2012
    ..To determine the most critical symptoms in a national myotonic dystrophy type 1 (DM1) population and to identify the modifying factors that have the greatest effect on the severity of these symptoms...
  3. pmc Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study
    Chad Heatwole
    Department of Neurology, University of Rochester, Rochester, NY 14642, USA
    J Clin Neuromuscul Dis 13:85-94. 2011
    ..To compare the short-term financial costs of treating a patient in myasthenia gravis crisis with intravenous immunoglobulin (IVIG) versus plasma exchange...
  4. pmc Laboratory abnormalities in patients with myotonic dystrophy type 2
    Chad Heatwole
    Neuromuscular Division, Department of Neurology, University of Rochester Medical Center, Rochester, NY 14642, USA
    Arch Neurol 68:1180-4. 2011
    ..Similar to DM1, this disease causes progressive debilitating weakness, clinical myotonia, and early cataracts and is thought to cause widespread physiologic dysfunction of multiple organ systems...
  5. pmc Open-label trial of recombinant human insulin-like growth factor 1/recombinant human insulin-like growth factor binding protein 3 in myotonic dystrophy type 1
    Chad R Heatwole
    University of Rochester Medical Center, Rochester, NY 14642, USA
    Arch Neurol 68:37-44. 2011
    ..To evaluate the safety and tolerability of recombinant human insulin-like growth factor 1 (rhIGF-1) complexed with IGF binding protein 3 (rhIGF-1/rhIGFBP-3) in patients with myotonic dystrophy type 1 (DM1)...
  6. ncbi request reprint International Education Issues: practicing and teaching international neurology: the Krakow experience
    Chad Heatwole
    The University of Rochester, 174 Edgemont Rd, Rochester, NY 14620, USA
    Neurology 69:1721-3. 2007
  7. ncbi request reprint Laboratory abnormalities in ambulatory patients with myotonic dystrophy type 1
    Chad R Heatwole
    Neuromuscular Disease Center, Strong Memorial Hospital, University of Rochester, 601 Elmwood Avenue, Rochester, NY 14642, USA
    Arch Neurol 63:1149-53. 2006
    ..Myotonic dystrophy type 1 (DM1) is the most prevalent form of adult muscular dystrophy worldwide. Although well known for the classic manifestations of myotonia, weakness, and early cataracts, it has broad effects on multiple organ systems...
  8. ncbi request reprint Extreme spindles: a distinctive EEG pattern in Mycoplasma pneumoniae encephalitis
    Chad R Heatwole
    University of Rochester, NY, USA
    Neurology 64:1096-7. 2005
  9. ncbi request reprint The nondystrophic myotonias
    Chad R Heatwole
    Department of Neurology, University of Rochester, Rochester, New York, USA
    Neurotherapeutics 4:238-51. 2007
    ....
  10. pmc Reevaluating measures of disease progression in facioscapulohumeral muscular dystrophy
    Jeffrey M Statland
    Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
    Neuromuscul Disord 23:306-12. 2013
    ....
  11. doi request reprint Evoked myotonia can be "dialed-up" by increasing stimulus train length in myotonic dystrophy type 1
    Eric L Logigian
    Department of Neurology, University of Rochester Medical Center, Box 673, 601 Elmwood Avenue, Rochester, New York, USA
    Muscle Nerve 41:191-6. 2010
    ..Evoked myotonia testing utilizing a stimulus paradigm of at least 20 stimuli at 30-50 HZ may be useful in antimyotonic drug trials, particularly when grip RT is normal or equivocal...